An Ensemble of Virtual Screening Methods Proves Successful

Jun 16 2017

virtual screeningThe identification of lead molecules showing pharmacological activity against a biological target is a key focal point of early-stage drug discovery. Virtual screening can play a vital role by finding novel hits early in the drug discovery process and has proven to be an invaluable tool in supporting fast and cost-efficient lead discovery.

The combination of ligand- and structure-based virtual screens can be a positive integrated hit finding approach as demonstrated in targeting LRRK2, a member of the leucine-rich repeat kinase family associated with an increased risk of Parkinson’s disease. A recent paper by Gancia, et al. published in Bioorganic & Medicinal Chemistry Letters describes a successful virtual screen (VS) against the kinase LRRK2 that provided tractable starting points for a hit optimization program.

According to the authors, the ligand-based virtual screen used the structures of competitor compounds as queries for a variety of 2D and 3D searches while the structure-based screen relied on homology models of LRRK2. From there, hundreds of compounds from the virtual screen were then tested, leading to the identification of 35 hits, 4 of which were deemed to have potential for medicinal chemistry follow-up. With this success, the use of combined ligand- and structure-based virtual screening can be considered as an option when designing certain hit finding approaches.

You may also be interested in...

Filling the Drug Discovery Abyss

Thought leaders in science and business are coming together by pairing scientific excellence with efficient, decentralized novel business models to stock the drug development pipelines of tomorrow.

Medicinal Chemists: The Architects of Drug Discovery

Today’s medicinal chemists must not only be innovative, versatile, and knowledgeable in their own field, but they must also be well versed in a range of other disciplines to help move programs forward in the drug discovery process.